Preclinical discovery and clinical development of encorafenib for the treatment of melanoma.

Abstract excerpt

INTRODUCTION: Nearly 50% of patients with metastatic melanoma harbor a BRAFV600-mutation, which can be targeted with the use of BRAF and MEK inhibitors, either in the front-line or treatment-refractory setting. Encorafenib is the newest BRAF-inhibitor to have received FDA-approval in combination with the MEK inhibitor binimetinib. AREAS COVERED: The authors provide an overview of the preclinical development and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Carbamates
• Share to Drug Development
• Share to Drug Discovery